Abstract
Background: Choroidal neovascularization (CNV), also known as subretinal neovascularization, causes serious damage to the central vision as it happens more commonly in macula. The most important factor involved in angiogenesis is vascular endothelial growth factor (VEGF). By an RNAi technique, VEGF gene knockdown can be used to treat CNV. PEG-conjugated poly (amidoamine) (PEGPAMAM) dendrimers as a new type of synthetic polymers are very promising to be gene delivery carriers.
Methods: To investigate siRNA delivery efficacy of PEG-PAMAM dendrimers, we prepared dendriplexes of PEG-PAMAM dendrimers with a fluorescence-labelled siRNA (PEG-PAMAM/FAM siRNA) or VEGF siRNA (PEG-PAMAM/VEGF siRNA), and studied transfection and downregulation efficacy of the dendriplexes in a cobalt chloride (CoCl2)-induced neovascularization model in retinal vascular endothelial cells (RF/6A).
Results: Our results demonstrate that PEG-PAMAM dendrimers had significantly higher transfection efficiency to FAM siRNA than a commercial transfection reagent PEI (1.4-fold, P<0.001) measured by flow cytometry. Compared to the PEI/VEGF siRNA polyplexes, the dendriplexes of the PEG-PAMAM/VEGF siRNA more significantly downregulated VEGF gene expression (P < 0.01) at both mRNA and protein expression level. A tube formation assay also proved that the PEG-PAMAM/VEGF siRNA dendriplexes more significantly inhibited vascular-like formation than PEI/VEGF siRNA did (P < 0.001) in RF/6A.
Conclusion: This study demonstrated that G5-PEG was more efficient than PEI in facilitating siRNA delivery, downregulating VEGF expression and inhibiting vascular-like formation on RF/6A.
Keywords: Choroidal neovascularization, gene silencing efficacy, PEG-conjugated PAMAM dendrimers, retinal vascular endothelial cells, siRNA, vascular endothelial growth factor.
Current Drug Delivery
Title:Efficient siRNA Delivery Using PEG-conjugated PAMAM Dendrimers Targeting Vascular Endothelial Growth Factor in a CoCl2-induced Neovascularization Model in Retinal Endothelial Cells
Volume: 13 Issue: 4
Author(s): Lu Xu, Wenwen Shen, Bin Wang, Xinlei Wang, George Liu, Yong Tao and Rong Qi
Affiliation:
Keywords: Choroidal neovascularization, gene silencing efficacy, PEG-conjugated PAMAM dendrimers, retinal vascular endothelial cells, siRNA, vascular endothelial growth factor.
Abstract: Background: Choroidal neovascularization (CNV), also known as subretinal neovascularization, causes serious damage to the central vision as it happens more commonly in macula. The most important factor involved in angiogenesis is vascular endothelial growth factor (VEGF). By an RNAi technique, VEGF gene knockdown can be used to treat CNV. PEG-conjugated poly (amidoamine) (PEGPAMAM) dendrimers as a new type of synthetic polymers are very promising to be gene delivery carriers.
Methods: To investigate siRNA delivery efficacy of PEG-PAMAM dendrimers, we prepared dendriplexes of PEG-PAMAM dendrimers with a fluorescence-labelled siRNA (PEG-PAMAM/FAM siRNA) or VEGF siRNA (PEG-PAMAM/VEGF siRNA), and studied transfection and downregulation efficacy of the dendriplexes in a cobalt chloride (CoCl2)-induced neovascularization model in retinal vascular endothelial cells (RF/6A).
Results: Our results demonstrate that PEG-PAMAM dendrimers had significantly higher transfection efficiency to FAM siRNA than a commercial transfection reagent PEI (1.4-fold, P<0.001) measured by flow cytometry. Compared to the PEI/VEGF siRNA polyplexes, the dendriplexes of the PEG-PAMAM/VEGF siRNA more significantly downregulated VEGF gene expression (P < 0.01) at both mRNA and protein expression level. A tube formation assay also proved that the PEG-PAMAM/VEGF siRNA dendriplexes more significantly inhibited vascular-like formation than PEI/VEGF siRNA did (P < 0.001) in RF/6A.
Conclusion: This study demonstrated that G5-PEG was more efficient than PEI in facilitating siRNA delivery, downregulating VEGF expression and inhibiting vascular-like formation on RF/6A.
Export Options
About this article
Cite this article as:
Xu Lu, Shen Wenwen, Wang Bin, Wang Xinlei, Liu George, Tao Yong and Qi Rong, Efficient siRNA Delivery Using PEG-conjugated PAMAM Dendrimers Targeting Vascular Endothelial Growth Factor in a CoCl2-induced Neovascularization Model in Retinal Endothelial Cells, Current Drug Delivery 2016; 13 (4) . https://dx.doi.org/10.2174/1567201812666150817123049
DOI https://dx.doi.org/10.2174/1567201812666150817123049 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents
Current Protein & Peptide Science Mitochondrial Lipids as Apoptosis Regulators
Current Medicinal Chemistry Activation of p53 by Specific Agents in Potential Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets Antiproliferative and Antifungal Activities of 1,3-diarylpropane-1,3-diones Commonly used as Sunscreen Agents
Letters in Drug Design & Discovery Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma
Anti-Cancer Agents in Medicinal Chemistry Antiviral Medication in Sexually Transmitted Diseases. Part I: HSV, HPV
Mini-Reviews in Medicinal Chemistry Immunotherapy in Gastric Carcinoma: Current Status and Future Perspectives
Clinical Cancer Drugs Two Orthogonal Approaches to Overcome Multi-Drug Resistant HIV-1s: Development of Protease Inhibitors and Entry Inhibitors Based on CXCR4 Antagonists
Current Drug Targets - Infectious Disorders Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design CB 1954: From the Walker Tumor to NQO2 and VDEPT
Current Pharmaceutical Design Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Mechanisms of Cellular Resistance to Camptothecins
Current Medicinal Chemistry Modulation of MicroRNAs by <i>Euphorbia Microsciadia</i> Boiss in MDA-MB-231 Cell Line: New Possibilities in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Heme Oxygenase and the Skin in Health and Disease
Current Pharmaceutical Design Site-Selective, Chemical Modification of Protein at Aromatic Side Chain and Their Emergent Applications
Protein & Peptide Letters